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 INTRODUCTION
The pain and stress associated with dehorning has 
been evaluated using changes to physiology, behavior, 
and the neuroendocrine system (Stafford and Mellor, 
2011). Analysis of affective states such as pain and 
distress are often achieved through the measurement 
of indirect measures such as changes in the hypo-
thalamic–pituitary–adrenal axis (McMeekan et al., 
1998), autonomic nervous system response (Stewart 
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ABSTRACT: The objective of this study was to 
investigate the effects of carprofen administered 
immediately before cautery dehorning on nocicep-
tion and stress. Forty Holstein calves aged approxi-
mately 6 to 8 wk old were either placebo treated and 
sham dehorned (n = 10) or cautery dehorned follow-
ing administration of carprofen (1.4 mg/kg) subcuta-
neously (n = 10) or orally (n = 10) or a subcutaneous 
and oral placebo (n = 10) in a randomized, controlled 
trial. All animals were given a cornual nerve block 
using lidocaine before dehorning. Response variables 
including mechanical nociception threshold, ocular 
temperature, heart rate, and respiratory rate were 
measured before and following cautery dehorning 
for 96 h. Blood samples were also collected over 96 
h following dehorning and analyzed for plasma cor-
tisol and substance P concentrations by RIA. Plasma 
carprofen concentration and ex vivo PGE2 concen-
trations were also determined for this time period. 
Average daily gain was calculated for 7 d after 
dehorning. Data were analyzed using a linear mixed 
effects model with repeated measures, controlling for 
baseline values by their inclusion as a covariate in 
addition to planned contrasts. Dehorning was associ-
ated with decreased nociception thresholds through-
out the study and a stress response immediately after 
dehorning, following the loss of local anesthesia, and 
48 h after dehorning compared with sham-dehorned 
calves. Carprofen was well absorbed after adminis-
tration and reached concentrations that inhibited ex 
vivo PGE2 concentrations for 72 h (subcutaneous) 
and 96 h (oral) compared with placebo-treated calves 
(P < 0.05). Carprofen-treated calves tended to be less 
sensitive (P = 0.097) to nociceptive threshold tests. 
Overall, at the dosing regimen studied, the effect of 
carprofen on sensitivity and stress following cautery 
dehorning was minimal. Consideration of route of 
administration and dose determination studies may 
be warranted.
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et al., 2008), and behavior (Faulkner and Weary, 2000). 
Despite these previously reported changes following a 
noxious event, there are currently no approved anal-
gesics for cattle in the United States (Coetzee, 2013a).
Several pain mitigating strategies have been eval-
uated. Through reductions in cortisol, a multimodal 
approach to analgesia including the use of local an-
esthesia (McMeekan et al., 1998), nonsteroidal anti-
inflammatory drugs (NSAID; Huber et al., 2013), or 
sedatives (Stilwell et al., 2010) may provide optimal 
pain relief (Coetzee, 2013b). Furthermore, in addition 
to the fundamental use of local anesthesia in cautery 
dehorning, analgesics with persistent activity may be 
beneficial (Heinrich et al., 2010).
Carprofen is an NSAID with a prolonged half-life 
in cattle that is administered as a racemic (RS±) mix-
ture (Brentnall et al., 2013). Currently, it is approved 
in countries in Europe as an adjunctive treatment for 
inflammation associated with pneumonia in young 
calves. Carprofen has demonstrated both cyclooxy-
genase (COX)-dependent (Miciletta et al., 2014) and 
COX-independent mechanisms including attenuating 
IL-6, a proinflammatory cytokine in equine synovio-
cytes and chondrocytes (Armstrong and Lees, 2002). 
As IL-6 has been reported to mediate the pain associ-
ated with burns in rodents, carprofen may provide ef-
fective pain management following cautery dehorning 
(Summer et al., 2008).
The objective of our study is to investigate the ef-
fect of perioperatively administered carprofen on no-
ciception and stress following cautery dehorning.
MATERIALS AND METHODS
Animals and Housing
Forty Holstein calves (18 castrated males and 
22 females) with a mean age of 50.9 d (SD 5.3) and 
mean weight of 63.8 kg (SD 8.7) at dehorning were 
included in this study. Calves were obtained from the 
Iowa State University Dairy (Ames, IA) and weaned 
at approximately 4 wk of age. Male calves were band 
castrated within the first week of life according to on-
farm practices. The scrotum of 1 animal was present 
at the time of enrollment but was included in the study 
due to a lack of swelling or inflammation observed 
and a healthy physical examination. The castration 
sites for all other animals had healed. All calves were 
determined healthy by a physical examination by a 
veterinarian. This study protocol was approved by the 
Institutional Animal Care and Use Committee at Iowa 
State University (log number 5-13-7566-B).
Calves were housed in a naturally ventilated group 
housing facility on the Iowa State University Dairy. A 
total of 5 groups of 8 animals were moved from in-
dividual 3-sided pens into group housing at least 6 d 
before dehorning for environmental and social accli-
matization. Group pens (3.7 by 6.4 m) were bedded 
with straw added daily. Water and grain, consisting of 
primarily pelleted corn, oats, molasses protein/vita-
min/mineral supplement, and monensin, were fed to 
the calves ad libitum for the duration of the trial (Table 
1). The study was conducted in July and August.
Animals were monitored twice daily for health 
observations. Animals appearing depressed or lethar-
gic were examined by a veterinarian and monitored 
or treated accordingly. Veterinarian diagnosed re-
spiratory disease was diagnosed based on persistent 
elevated rectal temperature (>39.7°C), spontaneous 
cough, and ocular and/or nasal discharge. Respiratory 
disease was treated using tulathromycin (2.5 mg/kg; 
Draxxin; Pfizer Inc., New York, NY) with resolution 
of clinical signs following treatment. Overall, 1 ani-
mal was treated in the non-dehorned, placebo treated 
(SHAM) group, 2 animals were treated in both the 
oral carprofen, dehorned (PO) and placebo-treated de-
horned (PLCBO) groups, and 3 animals were treated 
in the subcutaneous carprofen, dehorned (SQ) group 
throughout the length of the study. Treatment of re-
spiratory disease did not include administration of an 
NSAID. Calves did not require further treatment for 
any other disease process.
Study Design
A randomized controlled trial design was used 
for this investigation. Study animals were randomly 
assigned to be either placebo treated and SHAM de-
horned (SHAM; n = 10) or cautery dehorned following 
administration of carprofen (1.4 mg/kg) orally (PO; n 
= 10) or subcutaneously (SQ; n = 10) or a subcutane-
ous and oral placebo (PLCBO; n = 10; Fig. 1). All ani-
mals were administered an oral bolus and an injection. 
Animals not enrolled in the oral carprofen group were 
administered an oral lactose placebo and those animals 
not enrolled in the SQ group were given an injection 
of sterile saline. Randomization of group assignments 
Table 1. As-fed (%) components of the grain diet pro-
vided to calves throughout the study
Component As fed, %
Corn 50
Oats 5
Commercial supplement1 (38% protein) 30
Commercial supplement (34% protein) 10
Liquid molasses 5
1Contains monensin.
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was accomplished using a computer generated random 
number (Microsoft Excel 2011; Microsoft Corporation, 
Redmond, WA) with animals blocked by weight within 
sex. Following randomization and group assignment, 
calves were enrolled in 1 of 4 treatment groups (n = 
10) containing equal number of animals. Five phases 
of 8 calves per phase were used during a 6-wk period 
of time. Two animals from each treatment group were 
represented in each phase (n = 2 calves/treatment for 
each phase) and animals in each phase were housed in 
equivalent pens.
A jugular catheter was placed for the purpose of 
blood sample collection. Placement of the jugular cath-
eter occurred approximately 12 h before the start of the 
investigation. Calves were restrained by a handler dur-
ing the process of catheter placement. The area over 
the jugular vein was clipped and surgically prepared 
with alternating scrubs of 70% isopropyl alcohol and 
povidone iodine. The catheter site was infiltrated with 
2% lidocaine injection, 1 mL subcutaneously (Phoenix; 
Sparhawk Laboratories, Inc., Lenexa, KS). Using ster-
ile technique, an 18-gauge by 55-mm intravenous 
catheter (SURFLO; Terumo Medical Corp., Somerset, 
NJ) with injection plug (Hospira Inc., Lake Forest, IL) 
was inserted into the vein and sutured to the skin using 
number 3 nylon suture (Ethilon; Ethicon, San Lorenzo, 
PR). Catheter patency was maintained by flushing 
with 3 mL of a heparin saline solution containing 3 
United States Pharmacopeia units heparin sodium/mL 
saline (Heparin Sodium Injection; Baxter Healthcare, 
Deerfield, IL). The catheter port was disinfected with 
an alcohol swab before sample collection.
Study animals (n = 10) were administered SQ car-
profen (1.4 mg/kg; Rimadyl Injectable, 50 mg/mL; new 
animal drug application [NADA] number 141-199; 
Pfizer Inc.) under the skin in the cervical muscular re-
gion. The dose was rounded to the nearest tenth millili-
ter and administered in a 3-mL syringe. Calves enrolled 
in the other groups not administered SQ carprofen (PO, 
PLCBO, and SHAM) were given an equivalent amount 
of 0.9% saline subcutaneously in the same manner pre-
viously described.
Oral carprofen (1.4 mg/kg) administration was 
completed using tablets of 2 different concentrations 
to provide the most accurate targeted dose. Either 
100-mg tablets (Novox Caplets, abbreviated NADA 
[ANADA] number 200-498; Vedco, Inc., St. Joseph, 
MO) or 75-mg tablets (Novox Caplets, ANADA num-
ber 200-498; Vedco, Inc.) were provided to calves in 
a small gelatin capsule (Torpac, Inc., Fairfield, NJ) 
administered using an oral balling gun. Using the 2 
different formulations, the dose was rounded to the 
nearest tablet of the weight determined 24 h before 
administration. Using these 2-tablet formulations, the 
actual mean dose of 1.40 mg/kg (range 1.13–1.63 mg/
kg) was administered to the calves as an oral bolus. 
Animals not given an oral carprofen (SQ, PLCBO, and 
SHAM) were identically administered a placebo (lac-
tose powder) encapsulated in the same gelatin bolus.
Dehorning
Dehorning was performed in 10-min intervals. 
Calves were restrained during dehorning using a mod-
ified calf restraining device (Easy B-Z Portable Calf 
Restraint; Nasco, Fort Atkinson, WI). Cautery dehorn-
ing was initiated 10 min following administration of 
the oral bolus, subcutaneous injection, and local anes-
thetic. All calves were given a local anesthetic before 
actual or sham cautery dehorning. Desensitization of 
the cornual tissue was provided via a cornual nerve 
block using 2% lidocaine (VetOne, Boise, ID; 5 mL/
site) as described by Stock et al (2013). Effective lo-
cal anesthesia of the cornual tissue was confirmed us-
ing a lack of behavior reactions (e.g., ear flicks, head 
shaking, strong escape behavior) to a needle prick 5 
min after administration of the cornual nerve block. 
Calves were cautery dehorning by placement of a 
preheated electrical hot iron (approximately 600°C; 
Dehorner X-50; Rhinehart Development Corporation, 
Spencerville, IN) on the horn tissue for approximate-
ly 15 to 20 s until a circumferential copper-colored 
ring surrounding the horn bud was formed after in-
Figure 1. Flow chart outlining the timing of the study events. Calves 
were dehorned and monitored for cortisol, substance P (SP), mechanical 
nociception threshold (MNT), ocular temperature (OT), heart rate (HR), 
ADG, ex vivo PGE2, and carprofen (CARP) concentration. The times in 
parentheses represent the duration of data collection for each variable. PO 
= oral carprofen, dehorned group; SQ = subcutaneous carprofen, dehorned 
group.
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vestigators confirmed adequate desensitization. A du-
plicate, nonheated electric dehorner (Dehorner X-50; 
Rhinehart Development Corporation) was identically 
used for SHAM animals. Each group of 8 study ani-
mals was dehorned by the same person to minimize 
variation within the phase.
The dehorning sites were monitored daily for 
signs of discharge or infection, in addition to an as-
sessment of attitude, posture, appetite, lying time, and 
perioperative swelling.
Blood Sample Collection
Animals were restrained during blood collection 
by trained handlers. Before blood collection, approxi-
mately 5 mL of blood was aspirated in the syringe and 
returned through the catheter 3 times to remove the 
heparin flush from the catheter. Baseline samples were 
obtained approximately 1 h before drug administra-
tion. Blood samples were collected for animals given 
carprofen or placebo via the catheter at 0.5, 0.75, 1, 2, 
4, 6, 8, 10, 12, 24, 48, 72, and 96 h (–10 min) follow-
ing dehorning. Samples were immediately transferred 
to a blood collection tube with either sodium hepa-
rin or EDTA (Vacutainer; BD Diagnostics, Franklin 
Lakes, NJ) and stored in a cooler with ice packs be-
fore processing. Blood samples were centrifuged for 
15 min at 1,500 × g at ambient temperature. Collected 
plasma was placed in cryovials and frozen at –80°C 
until analysis.
Calves were loosely restrained using the same 
head restraint as previously described approximately 
5 min before nociception threshold detection via pres-
sure algometry and infrared thermography at 4, 8, 12, 
24, 48, 72, and 96 h after dehorning. Blood collection 
would occur before calves were placed in the head 
restraint. After this brief period of acclimatization in 
the restraint device, infrared images were obtained. 
Following infrared thermography imaging, calves 
were blindfolded for pressure algometry nociception 
threshold testing to avoid conditioned withdrawal re-
flex based on visual cues. Baseline samples for heart 
rate, respiratory rate, ocular temperature, and mechan-
ical nociception threshold (MNT) were obtained 14 ± 
2 h before the initiation of the study.
Ocular Temperature
A thermography camera (FLIR SC 660; FLIR 
Systems AB, Boston, MA) with a thermal sensitiv-
ity of 0.05°C, 320 × 240 pixel display, and precision 
> 98% was used to quantify changes in ocular tem-
perature similarly described in Stock et al. (2013). The 
camera was internally calibrated to ambient tempera-
ture before image collection; however, additional min-
ute adjustments to ambient temperature and humidity 
were used during software processing. Images were 
obtained from the left side of the calf, at an angle of ap-
proximately 45° and a distance of 0.5 m from the eye. 
Maximum temperature (°C) within a circumferential 
area of the eye including the medial posterior palpebral 
border of the lower eyelid and the lacrimal caruncle 
was obtained as previously described (Stewart el al., 
2008). Images were analyzed using FLIR Tools (ver-
sion 4.1; FLIR Systems Inc., Boston, MA) following 
collection. At each time point, 3 images were obtained 
and the minimum temperature recorded was used for 
statistical analysis.
Mechanical Nociception Threshold
The MNT, as defined by a maximum force that in-
duces a withdrawal response, was determined at 4, 8, 
12, 24, 48, 72, and 96 h after dehorning as described 
in Tapper et al. (2011) and Stock et al. (2013). Briefly, 
using a hand-held pressure algometer (Wagner Force 
Ten FDX 25 Compact Digital Force Gage; Wagner 
Instruments, Riverside, CT), a force was applied per-
pendicular at a rate of approximately 1 kg of force 
per second at 2 locations (lateral and caudal) adjacent 
to the horn bud. The 1-cm2 rubber tip of the algom-
eter was placed immediately adjacent to cauterized 
skin. Additionally, a third control location between 
the eyes on the frontal bone was used to evaluate the 
MNT of an area that was not adjacent to cauterized 
skin. A withdrawal response was indicated by an overt 
movement away from the applied pressure algometer, 
which remained observable in the loose head restraint. 
The obtained pressure value was recorded by a sec-
ond researcher before observation from the investiga-
tor applying the pressure. A maximum value of 10 kgf 
was determined a priori. Calves were blindfolded be-
fore the MNT test to avoid a response associated with 
visual cues. Both the order of locations tested and the 
side of the calf the researcher stood on was random-
ized between each calf. Locations were tested 3 times 
in sequential order and the value was averaged for sta-
tistical analysis.
Heart and Respiratory Rate
Heart and respiratory rates were obtained before 
placement within the restraining device. Respiratory 
rates were obtained by a recorder outside of the group 
pen and heart rates were determined following a brief 
period of acclimatization of the recorder in the group 
pen. In this way, the restraining device would not in-
fluence respiratory and heart rates.
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Heart and respiratory rates were evaluated via 
auscultation at 3.5, 7.5, 11.5, 23.5, 47.5, 71.5, and 95.5 
h (±0.5). The bell of a stethoscope (Littmann, Master 
Classic II; 3M, St. Paul, MN) was placed between the 
third and fifth intercostal space and beats were count-
ed over a 15 s period. The value obtained was used 
to calculate beats per minute. Respiratory rates were 
calculated using the number of breaths observed per 
15 s and multiplying by 4.
Average Daily Gain
Animals were weighed using a Brecknell digital 
scale (PS500-36S; Avery Weigh-Tronix, Fairmont, 
MN). Average daily gain was calculated using weights 
obtained approximately 24 h before the carprofen ad-
ministration (d –1) and 7 d following dehorning (d 7). 
The scale was calibrated with weights of a known mass 
immediately before obtaining the weight of a calf.
Cortisol
Plasma cortisol concentrations were determined 
using a commercial RIA kit (Coat-A-Count Cortisol; 
Siemens Medical Solutions Diagnostics [formally 
Diagnostic Products Corp.], Los Angeles, CA) previ-
ously used for bovine plasma collected in heparin at 0.5, 
0.75, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, and 96 h (–10 min) 
after dehorning (Stilwell et al., 2008a). Samples were 
assayed in duplicate with the reported concentration 
equaling the average cortisol concentration between 
duplicates. The average intra- and interassay CV were 
8.2 and 7.8%, respectively. The area under the effect 
curve (AUEC) was calculated using the linear trapezoi-
dal method as previously described (Glynn et al., 2013).
Substance P
Substance P (SP) concentrations were analyzed 
as described by Van Engen et al. (2014) using nonex-
tracted plasma collected in EDTA at 0.5, 0.75, 1, 2, 4, 
6, 8, 10, 12, 24, 48, 72, and 96 h (–10 min) after de-
horning. Samples were assayed in duplicate with the 
reported concentration equaling the average SP con-
centration between duplicates. The CV for intra-assay 
variability was at 8.6% and the interassay variability 
was calculated at 8.4%. The AUEC was calculated us-
ing the linear trapezoidal method.
Prostaglandin E2
Ex vivo PGE2 concentrations were determined as 
described by Fraccaro et al. (2013). Blood collected from 
calves was placed into sterile vacuum tubes containing 
heparin at 2, 6, 12, 24, 48, 72, 96 h. Lipopolysaccharide 
(LPS) obtained from Escherichia coli 0111:B4 (Sigma-
Aldrich Corp., St. Louis, MO) in PBS was added at 10 
μg/mL to the heparinized whole blood and incubated 
for 24 h at 37°C. Baseline samples were incubated with 
and without LPS before administration of carprofen. The 
same volume of PBS was added to the negative control 
baseline samples. At the end of incubation, all samples 
were centrifuged at 400 × g for 10 min at ambient tem-
perature to obtain plasma. Methanol was added to plasma 
in a 1:5 plasma to methanol dilution, facilitating protein 
precipitation. Following centrifugation at 3,000 × g for 
10 min at ambient temperature, the supernatant was col-
lected and stored at –80°C. A commercial PGE2 ELISA 
kit (Cayman Chemical, Ann Arbor, MI) previously de-
scribed using methanol precipitated bovine plasma was 
used for determination of PGE2 concentration (Donalisio 
et al., 2013; Fraccaro et al., 2013). Samples were assayed 
in duplicate with the concentration equaling the average 
PGE2 concentration. Prostaglandin E2 was statistically 
analyzed and reported as a percent inhibition, which was 
calculated using the formula
(PGE2 – baseline PGE2/baseline PGE2) × 100  
 = percent inhibition,
in which PGE2 is the concentration of PGE2 after de-
horning at each sample time point and baseline PGE2 
was obtained before administration of carprofen. The 
CV for intra-assay variability was at 9.8% and the in-
terassay variability was calculated at 14.6%. One ani-
mal from each of the PLCBO and SQ treatment groups 
were removed from analysis due to laboratory error.
Carprofen Plasma Concentration
Plasma concentrations of carprofen (R and S en-
antiomers) were determined using HPLC (Agilent 
1100 Pump and Autosampler; Agilent Technologies, 
Santa Clara, CA) coupled with ion trap mass spec-
trometry detection (LTQ; Thermo Scientific, San Jose, 
CA). Plasma samples, plasma spikes, and blanks, 100 
μL, were mixed with 400 μL of acetonitrile to precipi-
tate plasma proteins. Diclofenac (10 μL of 5 ng/μL) 
was added as an internal standard to all samples. The 
samples were vortexed for 5 s and centrifuged for 20 
min at 2,000 × g at ambient temperature to sediment 
the protein pellet. The supernatant was poured off into 
dry down tubes and evaporated at 50°C with a flow of 
nitrogen in a Turbovap (Biotage, Charlotte, NC). The 
contents were reconstituted with 150 μL of 25% ace-
tonitrile in water. The samples were transferred to an 
autosampler vials fitted with a glass insert and centri-
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fuged at 2,000 × g for 10 min at ambient temperature 
before analysis.
For liquid chromatography–mass spectrometry 
analysis, the injection volume was set to 15 μL. The 
mobile phases consisted of A, 0.1% formic acid in wa-
ter, and B, 0.1% formic acid in acetonitrile, at a flow 
rate of 0.225 mL/min. A solvent gradient beginning at 
40% B with a linear gradient to 60% B in 5 min was 
used for analysis. Separation was achieved with a LUX 
Cellulose-1 chiral column, 50 by 2 mm and 3-μm par-
ticles (Phenomenex, Inc., Torrance, CA), maintained at 
40°C. S+ and R– carprofen was eluted at 4.4 and 4.9 
min, respectively, whereas diclofenac was eluted at 4.5 
min. Electrospray ionization (ESI) and full scan mass 
spectrometry was used for analyte detection. Carprofen 
was detected with negative ESI with MS3 fragmenta-
tion (272→228). Wideband activation in positive ESI 
mode was used to aid the loss of water from diclofenac 
during transition from the parent (m/z 297) to the frag-
ment ions. The sum of the intensities of ions at m/z of 
190, 226, and 228 were used for carprofen quantitation. 
The internal standard, diclofenac, was quantitated with 
the sum of the fragment ion intensities at m/z of 215, 
250, and 252. Sequences consisting of plasma blanks, 
calibration spikes, and bovine plasma samples were 
batch processed with a processing method developed 
in the Xcalibur software (Thermo Scientific). The pro-
cessing method automatically identified and integrated 
each peak in each sample and calculated the calibra-
tion curve based on a weighted (1/x) linear fit. Plasma 
concentrations of carprofen in unknown samples were 
calculated by the Xcalibur software based on the cali-
bration curve. Results were then viewed in the Quan 
Browser portion of the Xcalibur software. Twelve cali-
bration spikes were prepared in blank bovine plasma 
covering the concentration range of 5 to 20,000 ng/mL. 
Calibration curves exhibited a correlation coefficient 
(r2) exceeding 0.996 across the entire concentration 
range. Quality control samples at 15, 150, and 1,500 
ng/mL were prepared in bulk and run with each set of 
samples/calibrators. The variance of the quality control 
samples was within 2 to 10% of the nominal value.
Pharmacokinetic Analysis
A noncompartmental pharmacokinetic analysis 
was performed using computer software. The follow-
ing parameters were evaluated: area under the curve 
(AUC) from time 0 to infinity (AUC0–∞) and AUC 
from time 0 to last collected sample (AUC0–96) using 
the linear trapezoidal rule as well as the percent of the 
AUC extrapolated to infinity. The extrapolated portion 
of the AUC was determined by multiplying the last 
measured plasma concentration by the elimination rate 
constant (λz), the first-order terminal rate constant. The 
range of the λz was determined by visual inspection of 
the plasma profile and determined by linear regression 
of time and natural logarithm (ln) of the plasma con-
centration. The volume of distribution per bioavailabil-
ity was determined by dividing the dose by λz × AUC. 
Plasma clearance per bioavailability was determined 
by dividing the dose by AUC. In addition, elimination 
half-life, maximum plasma concentration, and time to 
maximum plasma concentration were determined. The 
relative bioavailability (F) was estimated by dividing 
the oral (mean AUC/dose) by the subcutaneous (mean 
AUC/dose).
Statistical Analysis
Analyses were performed in SAS 9.3 (SAS Inst. 
Inc., Cary, NC) using a general linear mixed effects 
model with repeated measures using a heterogeneous 
compound symmetry covariance matrix. Data ob-
tained from response variables including cortisol, SP, 
MNT, heart rate, and respiratory rate were natural log-
arithm transformed for normality. In addition, PGE2 
percent inhibition was natural logarithm transformed 
for normality using the equation ln(PGE2 % inhibi-
tion + 101) to transform the negative percent. Baseline 
values were used as covariates. The fixed effects were 
treatment (carprofen PO, carprofen SQ, PLCBO, and 
SHAM), time, and the interaction between treatment 
and time. The effect of sex was included for all statis-
tical models. Phase was a random effect and calf was 
the subject of repeated measures. In order to test the 
significance of main effects and interactions, F-tests 
were used. If significant overall differences were iden-
tified among levels of a factor, pairwise comparisons 
were performed using Tukey’s t tests. Paired t tests 
were performed to test the differences between LPS-
stimulated and unstimulated baseline ex vivo PGE2 
concentrations. Planned contrasts were performed 
evaluating the responses of carprofen- (PO and SQ) 
versus PLCBO-treated calves following dehorning as 
well as the response following actual (PO, SQ, and 
PLCBO) or sham (SHAM) dehorning. These 3 con-
trasts are analyzed for the entire study along with at 
different time points (4, 8, 12, 24, 48, 72, and 96 h).
RESULTS AND DISCUSSION
The Animal Medicinal Drug Use Clarification 
Act (AMDUCA) permits the use of medicines to be 
used in an extra-label manner provided specific re-
quirements are met (FDA, 1994). As no drugs are cur-
rently labeled in cattle for analgesia or those that are 
labeled as anti-inflammatory have unknown analgesic 
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properties following a single dose, the use of carpro-
fen would constitute extra-label drug use permitted 
under AMDUCA. Following an intravenous (IV) or 
SQ dose of 1.4 mg/kg, a 14-d slaughter withhold pe-
riod is required in the European Union using the ap-
proved European formulation. Because there is a zero 
tolerance on the presence of violative residues under 
AMDUCA for extra-label drug use and carprofen dem-
onstrates age-related pharmacokinetics, additional tis-
sue residue studies are needed before recommendation 
of withholding times in young calves.
Carprofen
Carprofen was well absorbed following both sub-
cutaneous and oral administration (Tables 2 and 3). 
Although carprofen is administered as a racemic mixture, 
the S(+) enantiomer has been reported to be primarily 
responsible for the observed PG inhibition (Brentnall 
et al., 2013). Using AUC0–∞, the observed enantiomer 
ratio, R:S, was 57:43 for both oral and subcutaneous 
administration. This ratio is nearly identical to that pre-
viously reported following IV administration (Delatour 
et al., 1996). In the present study, both SQ and PO ad-
ministration of carprofen demonstrated a small volume 
of distribution as well as a slow clearance, resulting 
in prolonged median half-lives, S(+) = 52.8 h (range 
38.3–180.7 h) and S(+) = 49.7 h (range 38.4–79.2 h), 
respectively. These values are longer than the previous-
ly published mean half-life of 43.4 ± 2.3 h (RS±; R(–), 
49.7 ± 3.9 h, and S(+), 37.4 ± 2.4 h) in 8- to 10-wk-old 
calves (Delatour et al., 1996). Carprofen-S(+) achieved 
a mean maximum concentrations of 5.3 ± 0.9 μg/mL at 
9 h following SQ administration and 3.9 ± 0.8 μg/mL at 
18 h following PO dosing. The relative bioavailability 
of PO carprofen in comparison with SQ calculated us-
ing mean AUC0–96 was approximately 70%.
The pharmacokinetics in the present study indicat-
ed a longer mean half-life than previously reported in 
animals of similar age (Delatour et al., 1996). This may 
Table 2. Pharmacokinetic parameters following a noncompartmental analysis for carprofen (RS±; Vedco, Inc., 
St. Joseph, MO) orally administered before cautery dehorning (mean dose, 1.4 mg/kg; range, 1.13 to 1.63 mg/kg) 
Parameter1
R(–) S(+)
Mean SD Minimum Median Maximum Mean SD Minimum Median Maximum
AUC extrapolated to ∞, % 37.1 10.6 21.0 35.6 57.2 31.0 9.5 19.2 31.6 49.6
AUC0→∞, h × μg/mL 518.2 143.4 321.1 519.5 786.8 394.5 114.6 239.8 371.0 565.5
AUC0→96 h, h × μg/mL 314.1 50.5 242.8 318.1 382.9 265.6 60.8 193.7 257.9 358.6
Cl/F, mL∙ kg−1 ∙ h−1 1.45 0.41 0.89 1.36 2.18 1.92 0.57 1.24 1.89 2.92
Cmax, μg/mL 4.41 0.63 3.53 4.58 5.16 3.94 0.84 2.82 3.70 5.14
T1/2λz, h 62.8 18.5 39.3 58.1 97.0 52.9 14.5 38.4 49.7 79.2
λz, 1/h 0.012 0.0032 0.0071 0.012 0.018 0.014 0.0032 0.0088 0.014 0.018
Tmax, h 26.4 12.4 12 24 48 22.8 14.4 12 18 48
Vz/F, mL/kg 124.0 23.7 93.2 117.7 161.2 140.8 36.5 90.3 138.1 210.1
1AUC = area under the curve; AUC0→∞ = AUC from time 0 to infinity; AUC0→96 h = AUC from time 0 to last collected sample; Cl/F = plasma clear-
ance per bioavailability; Cmax = maximum plasma concentration; T1/2λz = elimination half-life; λz = elimination rate constant; Tmax = time to maximum 
plasma concentration; Vz/F = volume of distribution per bioavailability.
Table 3. Pharmacokinetic parameters following a noncompartmental analysis for carprofen (RS±; Pfizer Inc., 
New York, NY) subcutaneously administered before cautery dehorning (1.4 mg/kg)
Parameter1
R(–) S(+)
Mean SD Minimum Median Maximum Mean SD Minimum Median Maximum
AUC extrapolated to ∞, % 43.1 16.1 26.5 42.1 77.2 33.9 15.5 19.3 29.7 70.3
AUC0→∞, h × μg/mL 753.6 458.5 383.5 656.3 1,969.6 557.7 368.6 266.2 433.1 1,526.5
AUC0→96 h, h × μg/mL 369.6 59.6 284.1 369.4 463.2 319.6 77.7 214.9 307.0 452.7
Cl/F, mL∙ kg−1 ∙ h−1 1.14 0.45 0.34 1.06 1.80 1.58 0.63 0.46 1.62 2.63
Cmax, μg/mL 5.74 0.57 4.76 5.66 6.74 5.27 0.85 4.24 5.10 6.61
T1/2λz, h 89.3 58.6 47.9 75.7 242.7 66.7 42.6 38.3 52.8 180.7
λz, 1/h 0.0098 0.0040 0.0029 0.0092 0.014 0.013 0.0043 0.0038 0.013 0.018
Tmax, h 6 6 12 6 9 12
Vz/F, mL/kg 118.3 16.1 79.3 122.2 138.3 124.5 20.6 90.9 130.5 147.3
1AUC = area under the curve; AUC0→∞ = AUC from time 0 to infinity; AUC0→96 h = AUC from time 0 to last collected sample; ; Cl/F = plasma clear-
ance per bioavailability; Cmax = maximum plasma concentration; T1/2λz = elimination half-life; λz = elimination rate constant; Tmax = time to maximum 
plasma concentration; Vz/F = volume of distribution per bioavailability.
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be a result of using a younger population of animals in 
the present study. Age-dependent pharmacokinetics of 
carprofen has been reported in calves, with concentra-
tions persisting longer in younger animals (Delatour et 
al., 1996; Brentnall et al., 2013). Longer half-lives in 
younger calves are suggested to be a result of a reduc-
tion in clearance, which is consistent with our findings 
(Lees et al., 1996, Delatour et al., 1996). It should be 
noted that the AUC0–∞ observed in our study should 
be interpreted with caution due to the large percent of 
the AUC extrapolated to infinity.
Analgesic concentrations of NSAID have been 
previously estimated using a calculated 80% inhibi-
tory concentration (IC80) concentration of COX-2 
inhibition (Lees et al., 2004; Huntjens et al., 2005). A 
recent study evaluating in vitro COX-2 inhibition us-
ing a bovine whole blood assay indicted an IC80 equal 
to a mean total carprofen (RS±) concentration of 8.9 
μg/mL (range 1.9–42.9 μg/mL; Miciletta et al., 2014). 
Interestingly, it was reported that the R(–) enantiomer 
may attenuate COX inhibitory activity of the S(+) enan-
tiomer (Miciletta et al., 2013). Assuming these concen-
trations provide pain relief, using total carprofen con-
centrations with a similar enantiomer ratio as derived in 
our study, SQ administration would provide analgesia 
from approximately 4 to 24 h of time; however, a direct 
comparison between studies should be interpreted with 
caution given differences in study design. Oral admin-
istration did not achieve this target mean concentration 
throughout the course of the study. These data would 
potentially support the current daily regimen of SQ ad-
ministration to achieve the previously reported IC80; 
however, the duration above the IC80 observed in this 
study is shorter than that previously reported using the 
S(+) enantiomer alone (Brentnall et al., 2013). This may 
due to the interaction of the R(–) enantiomer given the 
enantioselectivity observed following administration of 
the racemic mixture in calves as reported by Miciletta 
et al. (2014).
Prostaglandin E2
An effect of treatment (P < 0.0001) and time (P 
< 0.0001) was observed on PGE2 percent inhibition 
(Table 4). Moreover, there was an interaction of time 
and treatment (P < 0.0001). Percent inhibition was in-
creased for calves subcutaneously administered carpro-
fen compared with placebo-treated controls from the ini-
tial collection time point of 2 h through 72 h (P < 0.05; 
Fig. 2). In addition, the percent inhibition was increased 
in calves orally treated with carprofen from 6 through 
96 h compared with placebo-treated controls (P < 0.05; 
Fig. 2). Prostaglandin percent inhibition was significant-
ly decreased in sham-dehorned calves compared with 
calves treated with carprofen for all time points (P < 
0.05). No difference was observed in PG inhibition be-
tween placebo-treated dehorned calves compared with 
those sham dehorned (P > 0.1). Baseline PGE concen-
trations of LPS-stimulated blood was greater than un-
stimulated blood (P < 0.0001).
Nonsteroidal anti-inflammatory drugs inhibit COX 
isoenzymes responsible for producing PG, which in-
crease nociception, thereby increasing the sensitivity 
for nerve transmission at the site of injury (Basbaum 
et al., 2009). Carprofen is known to be a weak inhibi-
tor of cyclcoxygenase (Delatour et al., 1996; Lees et 
al., 1996). As such, the mechanism of action of this 
NSAID is thought to be both COX dependent and COX 
independent. In addition to inhibition of PG (Brentnall 
et al., 2013; Miciletta et al., 2013, 2014), the effect of 
carprofen may be mediated through reductions in pro-
inflammatory IL-6, observed in an equine in vitro study 
(Armstrong and Lees, 2002). In our study, ex vivo PGE 
concentrations were persistently decreased for the dura-
tion of the study in carprofen-treated calves compared 
with placebo-treated controls; however, only a moder-
ate overall reduction was observed in comparison with 
other NSAID demonstrating up to 100% PG inhibition 
using tissue cage models evaluating PGE2 inhibition in 
exudate (Lees et al., 2004).
Multiple studies have used in vitro assays to mea-
sure the effect and potency of carprofen on PGE in-
hibition (Brentnall et al., 2013; Miciletta et al., 2014). 
However, in our study, ex vivo PGE inhibition was used 
to determine the duration of effect following a single 
dose. Determination of ex vivo PGE concentrations in-
Figure 2. Back transformed mean (±SE) ex vivo PGE2 percent inhi-
bition over 96 h in carprofen- and placebo-treated calves after dehorning. 
PO = oral carprofen, dehorned group; SQ = subcutaneous carprofen, de-
horned group; PLCBO = placebo-treated dehorned group; SHAM = non-
dehorned, placebo treated group.
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cludes the effect of the parent compound in in vivo enan-
tiomer ratios as well as any contribution from circulating 
metabolites. It is unknown if carprofen metabolites are 
responsible for inhibition of PG. Glucuronide and CoA 
thioester metabolites of ketoprofen, an NSAID of the 
same 2-arylpropionic acid class as carprofen, demon-
strate potent PG inhibition in vitro (Levoin et al., 2004). 
Although not measured in this study, active metabolites 
may explain the observed difference in inhibition of 
PGE between carprofen- and placebo-treated calves that 
persisted longer than 48 h with decreasing parent drug 
concentrations.
Cortisol
There was no effect of treatment on cortisol con-
centrations (P = 0.48). Cortisol concentrations were af-
fected over time (P < 0.0001; Fig. 3); however, there 
was no interaction of time and treatment (P = 0.22; 
Table 4). No treatment differences were observed in 
evaluating the overall cortisol (AUEC from time 0 to 
last collected sample; P = 0.51). Furthermore, no treat-
ment differences were observed when the AUEC was 
divided as follows: 0 to 2 (P = 0.64), 2 to 8 (P = 0.34), 
and 8 to 96 h (P = 0.55; Table 5).
Cortisol concentrations have been previously de-
scribed to increase in calves dehorned compared with 
those sham dehorned (Stafford and Mellor, 2005). 
Although changes in cortisol concentrations were ob-
served over time in this study, no overall treatment 
differences among the groups were observed. This 
differs from a previous study that reported decreased 
cortisol concentrations at 1 h after cautery disbudding 
compared with placebo-treated controls (Stilwell et 
al., 2012). These differences may be due to the route 
of administration, as carprofen was intravenously ad-
ministered in the previous study, potentially rapidly 
achieving greater concentrations.
Evaluating the effect of carprofen on the stress 
response in nonsurgical castration has yielded equivo-
cal results in older, 6-mo-old calves. A nonsignificant 
reduction in cortisol was observed in 1 study after IV 
carprofen (1.4 mg/kg) was given 20 min before band 
castration (Pang et al., 2006), whereas another study 
reported a significant decrease of cortisol 6 and 48 h 
after burdizzo clamp castration in calves subcutane-
ously treated with carprofen (1.4 mg/kg; Stilwell et al., 
2008b). Additional study is needed to determine the ef-
fect of carprofen on the stress response following nox-
ious stimuli.
Substance P
There was no effect of treatment (P = 0.77), time (P 
= 0.23), or interaction of time and treatment (P = 0.53) 
on SP concentrations (Table 4). Area under the effect 
curve and maximum SP concentrations were not dif-
ferent among treatment groups (Table 5). In response 
to cautery dehorning, meloxicam (Allen et al., 2013) 
administration decreased SP concentrations where as fi-
rocoxib (Stock et al., 2015) did not result in a difference 
compared with placebo-treated controls. Taken together 
with the lack of cortisol treatment differences, carpro-
fen administered at the study dose and routes given may 
not provide adequate analgesia following cautery de-
horning.
Interestingly, an effect of gender was observed 
(P = 0.005). with SP concentrations greater (0.11 ± 
0.039 pg/mL) in female calves compared with male 
calves. Differences in pain responses between sexes 
have been previously well documented (Fillingim 
et al., 2009). More recently, SP differences between 
sexes were reported in a rat model using a formalin-
evoked pain model resulting in SP release (Nazarian et 
al., 2014). Consistent with our study, female rats had 
an increase in SP release, which was determined to 
Figure 3. Back transformed geometric mean (±SE) cortisol concen-
trations over 12 (a) and 96 h (b) for carprofen- and placebo-treated calves 
after cautery dehorning. Time 0 signifies the time of dehorning. PO = oral 
carprofen, dehorned group; SQ = subcutaneous carprofen, dehorned group; 
PLCBO = placebo-treated dehorned group; SHAM = non-dehorned, pla-
cebo treated group.
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Table 5. Area under the effect curve and maximum cortisol and substance P concentration (geometric means 
[95% confidence intervals]) of carprofen- and placebo-treated calves after dehorning. n = 10 for all response 
variables evaluated
Response1
Carprofen2 Control3
P-value
SQ PO PLCBO SHAM
Mean (95% confidence interval)
Cortisol, nmol × h/L
AUEC0–96 1,087.9
a
(814.1 to 1,453.7)
1,145.8a
(850.9 to 1,542.9)
1,201.8a
(896.1 to 1,612.0)
898.4a
(669.6 to 1,205.3)
0.51
AUEC0–2 16.3
a
(12.1 to 21.8)
17.5a
(13.0 to 23.7)
20.0a
(14.8 to 26.9)
19.5a
(14.5 to 26.3)
0.64
AUEC2–8 80.1
a
(55.7 to 115.2)
94.0a
(64.8 to 136.5)
108.4a
(75.1 to 156.6)
69.6a
(48.2 to 100.6)
0.34
AUEC8–96 978.7
a
(715.4 to 1,338.9)
1,022.1a
(740.9 to 1,409.9)
1,058.1a
(770.3 to 1,453.2)
789.6a
(574.6 to 1,084.9)
0.55
Cmax, nmol/L 30.5a
(24.3 to 38.4)
29.4a
(23.3 to 37.2)
35.7a
(28.3 to 45.0)
28.1a
(22.3 to 35.4)
0.41
Substance P, pg × h/mL
AUEC0–96 1,599.3
a
(1,342.8 to 1,904.7)
1,625.5a
(1,364.9 to 1,936.2)
1,622.0a
(1,361.6 to 1,932.4)
1,586.5a
(1,332.0 to 1,889.9)
0.96
AUEC0–8 124.6
a
(107.4 to 144.5)
129.7a
(111.8 to 150.5)
134.8a
(116.1 to 156.4)
131.0a
(112.9 to 152.0)
0.70
AUEC8–96 1,473.9
a
(1,232.4 to 1,762.9)
1,494.4a
(1,249.5 to 1,787.5)
1,486.7a
(1,242.6 to 1,778.5)
1,454.5a
(1,215.9 to 1,739.9)
0.96
Cmax, pg/mL 23.1a
(18.9 to 28.2)
23.1a
(18.9 to 28.3)
23.6a
(19.3 to 28.8)
22.9a
(18.7 to 27.9)
0.98
a Within a row, means without a common superscript differ (P < 0.05).
1AUEC0–96 = area under the effect curve from time 0 to last collected sample; AUEC0–2 = area under the effect curve from time 0 to 2 h; AUEC2–8 = 
area under the effect curve from time 2 to 8 h; AUEC8–96 = area under the effect curve from time 8 to last collected sample; AUEC0–8 = area under the 
effect curve from time 0 to 8 h; AUEC8–96 = area under the effect curve from time 8 to last collected sample; Cmax = maximum plasma concentration.
2SQ = subcutaneous carprofen, dehorned group; PO = oral carprofen, dehorned group.
3PLCBO = placebo-treated dehorned group; SHAM = non-dehorned, placebo treated group.
Table 4. Summary table of backtransformed response variables (geometric means [95% confidence interval]) of 
carprofen- and placebo-treated calves after dehorning. n = 10 unless otherwise noted
Response
Carprofen1 Control2
Treatment,
P-value
Time,
P-value
Time ×
treatment,
P-value
SQ PO PLCBO SHAM
Mean (95% confidence interval)
MNT,3 kgf 0.71a
(0.56 to 0.88)
0.72a
(0.57 to 0.90)
0.58a
(0.46 to 0.73)
1.84b
(1.47 to 2.32)
<0.0001 <0.0001 0.99
O cular 
temperature, °C
38.4a
(37.7 to 39.0)
38.5a
(37.9 to 39.2)
38.1a
(37.5 to 38.8)
38.2a
(37.6 to 38.9)
0.65 <0.0001 0.26
H eart rate,  
beats/min
94.3a
(87.3 to 101.9)
98.5a
(91.3 to 106.2)
97.0a
(89.9 to 104.6)
90.4a
(83.7 to 97.8)
0.43 0.0092 0.96
R espiratory rate, 
breaths/min
40.5a
(37.1 to 44.1)
38.4a
(35.2 to 41.8)
36.1a
(33.1 to 39.3)
38.4a
(35.2 to 41.8)
0.20 0.086 0.25
ADG, kg/d 0.48a
(0.27 to 0.68)
0.92b
(0.71 to 1.12)
0.69ab
(0.48 to 0.90)
0.68ab
(0.47 to 0.88)
0.0081
Cortisol, nmol/L 10.5a
(8.4 to 13.2)
11.0a
(8.7 to 13.8)
11.9a
(9.5 to 15.0)
9.4a
(7.5 to 11.9)
0.48 <0.0001 0.22
S ubstance P,  
pg/mL
16.3a
(14.2 to 18.7)
17.0a
(14.8 to 19.5)
17.0a
(14.8 to 19.5)
16.4a
(14.3 to 18.9)
0.77 0.23 0.53
PGE2, % –65.6
4a
(–73.7 to –55.2)
–62.2a
(–70.7 to –51.5)
–21.74b
(–39.8 to 1.6)
–8.3b
(–28.5 to 17.5)
<0.0001 <0.0001 <0.0001
a,b Within a row, means without a common superscript differ (P < 0.05).
1SQ = subcutaneous carprofen, dehorned group; PO = oral carprofen, dehorned group.
2PLCBO = placebo-treated dehorned group; SHAM = non-dehorned, placebo treated group.
3MNT = mechanical nociception threshold.
4n = 9.
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be mediated by estradiol concentrations. In our study, 
although a difference was noted, the effect size was 
small. Additionally, previous castration in males may 
confound the observed results in this study. Additional 
studies are needed to further clarify the role of sexual 
dimorphism in SP release in cattle.
Mechanical Nociception Threshold
An effect of treatment was observed (P < 0.0001) 
on the mean MNT. Furthermore, there was an ef-
fect of time (P < 0.0001) but there was no interac-
tion between treatment and time (P = 0.99; Table 4). 
Sham-dehorned calves had an increased MNT at all 
collection time points (P < 0.001; Table 4; Fig. 4). No 
overall treatment differences were observed among 
individual treatment groups of dehorned calves; how-
ever, the overall mean MNT tended to be greater in 
carprofen-treated calves compared with those admin-
istered a placebo (P = 0.097).
Previous studies have evaluated MNT differences 
following actual or sham dehorning of calves (Heinrich 
et al., 2010; Tapper et al., 2011; Allen et al., 2013, 
Glynn et al., 2013). In these previous studies, calves 
were initially sham dehorned before actual dehorning 
to determine baseline MNT information. In this study, 
in addition to determining baseline MNT values, sham-
dehorned calves were included throughout the data 
collection period to help control for the effects of the 
study on the pressure algometry response. Due to the 
MNT differences observed between sham and actual 
dehorned calves throughout the study period, MNT ap-
pears to be a reliable measure of increased pain sensitiv-
ity associated with cautery dehorning. Although MNT 
did not return to baseline values following the duration 
of the study (4 d) for dehorned calves, partial thickness 
epidermal burns have been noted to induce mechanical 
hyperalgesia for up to 4 wk in rat thermal injury models 
(Summer et al., 2007).
Mechanical nociception threshold has been use-
ful in detecting nociception differences in dehorned 
calves treated with an analgesic. Heinrich et al. (2010) 
demonstrated decreased sensitivity as determined by 
increased MNT following the use of intramuscular 
meloxicam. Moreover, Tapper et al. (2011) reported an 
increased MNT in calves administered local anesthesia 
using ethanol for at least 3 d after dehorning compared 
with calves administered lidocaine. Although carpro-
fen administration tended to increase MNT through-
out the study period, further investigation is warranted 
to determine the improved sensitivity associated with 
carprofen administration.
Ocular Temperature
There was no effect of treatment on ocular tem-
perature (P = 0.65). An effect of time was observed (P 
< 0.0001); however, there was no interaction of time 
and treatment (P = 0.26; Table 4). Statistical analy-
sis of the average ocular temperature yielded results 
similar to the presented minimum recorded maximum 
ocular temperature. Previous studies have indicated 
an equivocal response of ocular temperature follow-
ing dehorning. Stewart et al. (2009) reported a de-
creased ocular temperature associated with the loss 
of local anesthesia following dehorning. Moreover, 
administration of meloxicam attenuated the decreased 
ocular temperature observed in placebo-treated calves 
after dehorning (Stewart et al., 2009); however, other 
investigations have not observed this same response 
(Glynn et al., 2013; Allen et al., 2013; Stock et al., 
2015). Differences in handling, study animals, and 
data collection technique may account for the differ-
ent results among studies. The similar ocular tempera-
ture profiles throughout the study of sham and actual 
dehorned calves might further support this statement.
Figure 4. Backtransformed geometric mean (±SE) mechanical no-
ciception threshold (MNT) as measured through pressure algometry over 
96 h for carprofen- and placebo-treated calves. Time 0 signifies the time 
of dehorning. Pressure tolerance did not return to baseline values by the 
conclusion of MNT measurement for animals dehorned. Sham dehorned 
animals were significantly different at all time points after dehorning (P < 
0.0001). PO = oral carprofen, dehorned group; SQ = subcutaneous carpro-
fen, dehorned group; PLCBO = placebo-treated dehorned group; SHAM = 
non-dehorned, placebo treated group.
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Heart Rate
There was no effect of treatment on heart rate (P 
= 0.43). An effect of time was observed (P = 0.0092); 
however, there was no interaction between treatment 
and time (P = 0.96; Table 4). Heart rate has been pre-
viously used to evaluate changes in the autonomic 
nervous system following noxious events in cattle 
(Stewart et al., 2009; Heinrich et al., 2010; Coetzee et 
al., 2012). Increased heart rate variability has been re-
ported in castrated or dehorned cattle as a result of an 
imbalance in the autonomic nervous system (Stewart 
et al., 2009; Stewart et al., 2008). Although previous 
reports have indicated a significant reduction in heart 
rate in calves administered meloxicam before dehorn-
ing, this effect was not observed in our study (Heinrich 
et al., 2010; Coetzee et al., 2012). Differences in an-
algesic potential between NSAID and method of data 
collection may be reasons for the reported differenc-
es. In previous investigations, heart rates were col-
lected using an electrical heart rate monitor (Coetzee 
et al., 2012) or obtained following blood collection 
(Heinrich et al., 2009), which differs from our study. 
It is noteworthy that no differences were observed be-
tween calves actually or sham dehorned, potentially 
indicating the influence of the repeated handling for 
data collection.
Respiratory Rate
Statistical analysis was performed with and with-
out calves treated for respiratory disease. Using data 
from all calves, respiratory rate was not affected by 
treatment (P = 0.20) or time (P = 0.086; Table 4). 
Moreover, treatment groups did not differ in response 
over time (P = 0.25). Although carprofen-treated 
calves tended to have an increased respiratory rate in 
comparison with placebo-treated calves (P = 0.094), 
this effect was not observed if calves treated for respi-
ratory disease were removed from the statistical anal-
ysis (P = 0.38). These results differ from a previous re-
port of increasing respiratory rates in placebo-treated 
calves compared with calves treated with meloxicam 
(Heinrich et al., 2009). The lack of agreement between 
studies may be due to differences in analgesic poten-
tial between NSAID, study design including housing 
differences, and the technique used to collect the data 
(Heinrich et al., 2009).
Average Daily Gain
Calves treated with oral carprofen had an increased 
ADG compared with those treated with subcutaneous 
carprofen (0.92 ± 0.10 vs. 0.48 ± 0.10 kg/d; P = 0.0039). 
No other differences were observed between treatment 
groups (P > 0.1). Changes in ADG are equivocal, with 
previous studies reporting no changes or increases com-
pared with placebo-treated controls (Baldridge et al., 
2011; Glynn et al., 2013; Coetzee et al., 2012 ; Stock 
et al., 2015). Greater increases were observed in older 
study populations undergoing amputation dehorning, 
suggesting the potential that dehorning has a larger im-
pact on weight gain in older calves after an invasive 
procedure (Baldridge et al., 2011; Glynn et al., 2013; 
Coetzee et al., 2012 ). We do not completely understand 
the exact mechanism of the difference in ADG observed 
between carprofen treatments in our study and these dif-
ferences may be a result of the small number of animals 
enrolled in each treatment group. Parameters that con-
tribute to changes in ADG such as grain consumption 
were not measured in our study. Given the sample size 
used in this study, further investigations into changes in 
ADG following carprofen administration are warranted.
Conclusion
Cautery dehorning in dairy calves resulted in in-
creased nociception throughout the 96-h study period. 
Carprofen administration reached concentrations that 
moderately inhibited ex vivo PG and were decreased for 
72 (SQ) and 96 h (PO) after administration compared with 
placebo-treated controls; however, analgesic responses 
between treatment groups subsequent to dehorning were 
minimal using a dose of 1.4 mg/kg administered orally or 
subcutaneously. Consideration of route of administration 
and dose determination studies are recommended.
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